Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

Fig. 6

Predictive values for the models. Forest plot of Cox multivariate analysis for the clinical model (A). Forest plot of Cox multivariate analysis for the radiomics model (B). Forest plot of Cox multivariate analysis for the combined model (C). Nomogram for estimating 1-year OS utilizing clinical features (D). Nomogram for estimating 1-year OS utilizing radiomic features (E). Nomogram for estimating 1-year OS utilizing combined clinical and radiomic features (F). Calibration curve for the clinical model (G). Calibration curve for the radiomics model (H). Calibration curve for the combined model (I). ROC curves for the clinical model (J). ROC curves for the radiomics model (K). ROC curves for the combined model (L). DCA of the clinical model (M). DCA of the radiomics model (N). DCA of the combined model (O)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us